Market News & Trends
Voyager Advances Collaboration With Neurocrine; Third Gene Therapy Development Candidate Selected
Voyager Therapeutics, Inc. recently announced that the joint steering committee with its collaborator Neurocrine Biosciences, Inc. has selected a development candidate in a gene therapy…
Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients With Glioblastoma
Shuttle Pharmaceuticals Holdings, Inc. recently announced it has entered into agreements with two additional site locations to administer the Phase 2 clinical trial of Ropidoxuridine…
Vivtex Enters New Research Agreement With Equillium to Develop GI-targeted Formulations for its First-in-Class Oral, Bi-Specific Peptide Therapy
Vivtex Corporation recently announced it has entered a research and licensing agreement with Equillium, Inc., a clinical-stage biotechnology company developing novel therapeutics to treat severe…
Nanoscope Therapeutics Announces End-of-Phase 2 Meeting With FDA & Plan to Initiate a Phase 3 Clinical Trial
Nanoscope Therapeutics Inc. recently announced a productive End-of-Phase 2 (EOP2) meeting with the US FDA for its clinical program evaluating MCO-010 for the treatment of…
Vico Therapeutics Announces Positive Interim Phase 1/2a Clinical Data of VO659 in Treatment of Huntington’s Disease
Vico Therapeutics B.V. recently announced new positive interim data in Huntington’s disease (HD) from the ongoing Phase 1/2a clinical trial of VO659, an investigational allele-preferential…
Biosplice Therapeutics Announces Initiation of AML & MDS Trial Sponsored by the National Cancer Institute
Biosplice Therapeutics, Inc. recently announced the US FDA has cleared the NCI-sponsored Investigational New Drug (IND) application for cirtuvivint. This small molecule inhibitor of CLK…
Vironexis Biotherapeutics Launches With FDA Clearance of IND Application for First-Ever Clinical Trial of an AAV-delivered Cancer Immunotherapy
Vironexis Biotherapeutics launched from stealth, unveiling its TransJoin AAV Gene Therapy Platform and a pipeline of more than ten product candidates for blood-based cancers, solid…
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
Monopar Therapeutics Inc. recently announced positive early data from its ongoing open-label MNPR-101-Zr Phase 1 imaging and dosimetry clinical trial confirming MNPR-101-Zr’s tumor targeting ability…
Cellares & Sony Announce a Joint Development Collaboration to Integrate Flow Cytometry-Based Sorting & Online Analysis Into an Automated, High-Throughput Cell Therapy Manufacturing Platform
Cellares and Sony Corporation recently announced a collaboration to jointly develop and integrate advanced flow cytometry-based cell analysis and sorting solutions into the Cellares Cell…
Enable Injections Announces Agreement with Sobi to Develop & Distribute Aspaveli in Combination With enFuse
Enable Injections, Inc. and Swedish Orphan Biovitrum AB (Sobi) recently announced an international development and distribution agreement for the enFuse Injector, for the subcutaneous delivery…
TFF Pharmaceuticals Announces Positive Preclinical Data From Bivalent Universal Influenza Vaccine Candidates
TFF Pharmaceuticals, Inc recently announced positive preclinical data advancing a multivalent universal influenza vaccine manufactured by TFF to protect against seasonal and pandemic viruses. The…
Agios Announces FDA Orphan Drug Designation Granted for Treatment of Myelodysplastic Syndromes
Agios Pharmaceuticals, Inc. recently announced the US FDA has granted orphan drug designation to the company’s novel pyruvate kinase (PK) activator tebapivat (AG-946) for the…
Ilya Pharma Receives Rare Pediatric Disease Designation From US FDA
Ilya Pharma recently announced that it has received a Rare Pediatric Disease Designation by the US FDA. About SAVI: STING-associated vasculopathy with onset in infancy…
BriaCell Reports Positive Overall Survival in Metastatic Breast Cancer
BriaCell Therapeutics Corp. recently announced positive overall survival data of its Phase 2 clinical study of Bria-IMT in combination with an immune check point inhibitor…
Evonik Starts Operation of New Spray Drying Facility for Pharmaceutical Oral Excipients
Evonik has officially opened a new facility for drying aqueous dispersions of EUDRAGIT polymers at its site in Darmstadt. The new double-digit million-euro excipient manufacturing…
Roivant Unveils New Pipeline Program of a Potential First-in-Class & Best-in-Category Inhaled Once-Daily Soluble Guanylate Cyclase Activator
Roivant recently announced its previously undisclosed pipeline program mosliciguat, a potential first-in-class, inhaled, once-daily sGC activator with targeted delivery to the lungs via dry powder…
Quotient Sciences & Vasa Therapeutics Announce Dosing of First Subjects With Novel Heart Failure Treatment
VS-041, a novel and potentially life-saving treatment for heart failure, developed by Vasa Therapeutics, a San Diego-based biotechnology company, has reached a major clinical milestone…
Incendia Therapeutics Enrolls First Patient in Phase 1c Clinical Trial of a Novel DDR1 Inhibitor
Incendia Therapeutics, a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment (TME), recently announced the first patient…
Belite Bio Announces First Patient Dosed in Phase 2/3 Trial of Tinlarebant for the Treatment of Stargardt Disease
Belite Bio, Inc recently announced that the first patient has been dosed at the Tokyo Medical Center in the Phase 2/3 portion of its DRAGON…
Incannex Healthcare Announces Strategic Financing for up to $60 Million
Incannex Healthcare Inc. recently announced it has entered into an agreement to issue up to $10 million in secured convertible notes to Arena Investors, LP…
